Authors : Hasegawa T; Office for Promoting Medical Research, Showa University, Tokyo, Japan.; Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.

Subjects: Anemia/Anemia/Anemia/*drug therapy ; Hematinics/Hematinics/Hematinics/*therapeutic use ; Hypoxia-Inducible Factor-Proline Dioxygenases/Hypoxia-Inducible Factor-Proline Dioxygenases/Hypoxia-Inducible Factor-Proline Dioxygenases/*therapeutic use

Source: Seminars in dialysis [Semin Dial] 2018 Nov; Vol. 31 (6), pp. 599-606. Date of Electronic Publication: 2018 Jun 17.Publisher: Blackwell Science Country of Publication: United States NLM ID: 8911629 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.

Authors : Battistella M; From Division of Nephrology, University Health Network, Toronto, Ontario, Canada.; Chan CT

Subjects: Renal Dialysis*; Anemia, Iron-Deficiency/Anemia, Iron-Deficiency/Anemia, Iron-Deficiency/*drug therapy ; Drug Resistance/Drug Resistance/Drug Resistance/*drug effects

Source: Seminars in dialysis [Semin Dial] 2013 Sep-Oct; Vol. 26 (5), pp. 537-40. Date of Electronic Publication: 2013 Jun 05.Publisher: Blackwell Science Country of Publication: United States NLM ID: 8911629 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem.

Authors : Singh AK; Renal Division, Brigham and Women's Hospital and Harvard Medical School Boston, Boston, Massachusetts.

Subjects: Renal Dialysis*; Anemia, Iron-Deficiency/Anemia, Iron-Deficiency/Anemia, Iron-Deficiency/*prevention & control ; Erythropoietin/Erythropoietin/Erythropoietin/*administration & dosage

Source: Seminars in dialysis [Semin Dial] 2013 Sep-Oct; Vol. 26 (5), pp. 531-4. Date of Electronic Publication: 2013 Jun 14.Publisher: Blackwell Science Country of Publication: United States NLM ID: 8911629 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Can reduction of inflammation improve ESA dose response?

Authors : Kovesdy CP; Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center and Memphis VA Medical Center, Memphis, Tennessee.

Subjects: Renal Dialysis*; Drug Resistance/Drug Resistance/Drug Resistance/*physiology ; Erythropoietin/Erythropoietin/Erythropoietin/*analogs & derivatives

Source: Seminars in dialysis [Semin Dial] 2013 Sep-Oct; Vol. 26 (5), pp. 540-2. Date of Electronic Publication: 2013 Jun 05.Publisher: Blackwell Science Country of Publication: United States NLM ID: 8911629 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Report

Erythropoietin-stimulating agents in chronic kidney disease: a response to hyporesponsiveness.

Authors : Parfrey PS

Subjects: Anemia/Anemia/Anemia/*drug therapy ; Anemia/Anemia/Anemia/*etiology ; Hematinics/Hematinics/Hematinics/*therapeutic use

Source: Seminars in dialysis [Semin Dial] 2011 Sep-Oct; Vol. 24 (5), pp. 495-7. Date of Electronic Publication: 2011 Sep 09.Publisher: Blackwell Science Country of Publication: United States NLM ID: 8911629 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?

Authors : Gupta G; Division of Nephrology, Department of Internal Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA.; Choi MJ

Subjects: Anemia/Anemia/Anemia/*drug therapy ; Hematinics/Hematinics/Hematinics/*therapeutic use; Anemia/Anemia/Anemia/etiology

Source: Seminars in dialysis [Semin Dial] 2011 Jul-Aug; Vol. 24 (4), pp. 379-81. Date of Electronic Publication: 2011 Jul 31.Publisher: Blackwell Science Country of Publication: United States NLM ID: 8911629 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Review

From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.

Authors : Coyne DW

Subjects: Randomized Controlled Trials as Topic*; Anemia/Anemia/Anemia/*therapy ; Erythropoietin/Erythropoietin/Erythropoietin/*therapeutic use

Source: Seminars in dialysis [Semin Dial] 2008 May-Jun; Vol. 21 (3), pp. 212-6. Date of Electronic Publication: 2008 Mar 18.Publisher: Blackwell Science Country of Publication: United States NLM ID: 8911629 Publication Model: Print-Electronic Cited Medium: Print ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Anemia management in cancer patients with chronic kidney disease

Authors : Sheron Latcha

Subjects: Male; Injections, Subcutaneous; Anemia

Source: Seminars in Dialysis. 32:513-519

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?

Authors : Guy Rostoker

Subjects: Male; Iron Overload; Time Factors

Source: Semin Dial

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Is there an established hemoglobin target range for patients undergoing chronic dialysis?

Authors : Hitesh H. Shah; Steven Fishbane

Subjects: Adult; Hemoglobins; 03 medical and health sciences

Source: Seminars in Dialysis. 31:415-419

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Anemia in conventional hemodialysis: Finding the optimal treatment balance.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Can reduction of inflammation improve ESA dose response?

Erythropoietin-stimulating agents in chronic kidney disease: a response to hyporesponsiveness.

Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?

From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.

Anemia management in cancer patients with chronic kidney disease

When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?

Is there an established hemoglobin target range for patients undergoing chronic dialysis?

اتصل بنا

اتبع